News

Most adults with pulmonary arterial hypertension (PAH) experience no worsening and may even see a reduction in the severity of their symptoms after being on treatment with Uptravi (selexipag) for up to about 1.5 years. That’s according to a new analysis of data from all patients who took…

Researchers have identified three proteins — NID1, C1QTNF1, and CRTAC1 — in the bloodstream of people with pulmonary hypertension (PH) whose presence accurately predicted the failure of the heart’s right ventricle (RV) and related outcomes, a study reports. The proteins may serve as biomarkers to assess disease progression and…

Endotronix has been cleared by U.S. regulators to launch a clinical trial testing its Cordella Sensor, an implanted device that measures the pressure in the blood vessels of the lungs, in people with heart failure that slightly limits their physical activity. The study, given the green light by…

The matrix around the heart’s cells does not shrink and may continue to undergo changes after pulmonary endarterectomy, or PEA, a surgery to remove blood clots from the pulmonary arteries that supply the lungs, a small study found. Researchers suggest that fibrosis, or scarring, may explain why the heart’s size…

The presence of pulmonary hypertension (PH) didn’t increase mortality after a heart transplant, according to a new study. The findings oppose earlier studies that suggested an increased mortality rate among transplant recipients with PH, which was considered a contraindication. A secondary analysis of a large transplant registry with 24…

The gene coding for insulin-like growth factor 1 (IGF1) may be involved in both pulmonary hypertension (PH) and pulmonary fibrosis (PF), offering a potential target for treating both diseases, a study suggests. That’s important because for many people with both PH and PF, a lung transplant may be…

An echocardiogram during pregnancy, particularly at the third trimester, may help in predicting a risk of persistent pulmonary hypertension of the newborn (PPHN), a study from China suggests. Echocardiograms, which measure heart function using sound waves, are noninvasive and widely used in diagnosing pulmonary hypertension (PH) in people,…

The U.S. Food and Drug Administration (FDA) has agreed to review an application seeking approval of sotatercept as a treatment for adults with pulmonary arterial hypertension (PAH). The FDA has given the application priority review, shortening the review time from the usual 10 months to six months. A decision…

Note: This story was updated Jan. 30, 2024, to correct the approved indications of available treprostinil formulations. Amid ongoing litigation, the U.S. Food and Drug Administration (FDA) has agreed to review an application from Liquidia that seeks to extend the approval of Yutrepia — an inhaled dry powder…

Corsair Pharma has secured $23 million in financing to support clinical testing of a skin patch for the delivery of treprostinil to treat pulmonary arterial hypertension (PAH), the company announced. The transdermal patch is intended to provide continuous and consistent levels of treprostinil, similar to those achieved with…

Treatment with VU6047534, an experimental therapy that blocks the activity of a specific type of serotonin receptor, reduced strain on the heart in a mouse model of pulmonary arterial hypertension (PAH) in a new study. The study, “Development of a Peripherally Restricted 5-HT2B Partial Agonist for Treatment…

A joint initiative between a Singapore-based medical technology company and Duke University is aiming to develop and commercialize artificial intelligence, or AI, tools for echocardiography — using ultrasounds to visualize the heart. Researchers from Us2.ai, the first new company created from an 11-country cardiovascular research platform, have teamed up…